HomeCompareKMSTF vs JNJ

KMSTF vs JNJ: Dividend Comparison 2026

KMSTF yields 62.31% · JNJ yields 3.36%● Live data

vsPost on X →
After 10 years · $10,000 invested · DRIP enabled
🏆 KMSTF wins by $709.0K in total portfolio value
10 years
KMSTF
KMSTF
● Live price
62.31%
Share price
$3.21
Annual div
$2.00
5Y div CAGR
0%
Payout ratio
50%
After 10 yrs · $10,000 · DRIP
Portfolio value
$729.0K
Annual income
$175,361.30
Full KMSTF calculator →
JNJ
Johnson & Johnson
● Live price
3.36%
Share price
$147.50
Annual div
$4.96
5Y div CAGR
5.8%
Payout ratio
55%
After 10 yrs · $10,000 · DRIP
Portfolio value
$20.0K
Annual income
$827.78
Full JNJ calculator →

Portfolio growth — KMSTF vs JNJ

📍 KMSTF pulled ahead of the other in Year 1

Annual dividend income

🛡️

Recession Test — Did They Cut Dividends?

How each stock treated shareholders during the 3 biggest crises of the last 20 years

Crisis PeriodKMSTFJNJ
2008–2009
GFC
— No data— No data
2020 Q1–Q2
COVID
— No data— No data
2022 Q4
Rate Hike
— No data— No data
Based on dividend payment history. "Increased" = dividend grew during crisis. "Maintained" = held within 3%. "Cut" = reduced by more than 3%.
📅

Dividend Calendar Overlap

Combined, KMSTF + JNJ cover 0 of 12 monthsgood coverage

Jan
Feb
Mar
Apr
May
Jun
Jul
Aug
Sep
Oct
Nov
Dec
KMSTF pays
JNJ pays
Both pay
Neither
💰

Tax Bracket Optimizer

Which stock is actually better after tax? Adjust your rate to find out.

KMSTF
Annual income on $10K today (after 15% tax)
$5,295.95/yr
After 10yr DRIP, annual income (after tax)
$149,057.10/yr
JNJ
Annual income on $10K today (after 15% tax)
$285.83/yr
After 10yr DRIP, annual income (after tax)
$703.61/yr
At 15% tax rate, KMSTF beats the other by $148,353.49/year in after-tax income after 10 years on $10,000
⚖️

Lazy Portfolio Split Optimizer

What's the optimal mix of KMSTF + JNJ for your $10,000?

KMSTF: 50%JNJ: 50%
100% JNJ50/50100% KMSTF
Portfolio after 10yr
$374.5K
Annual income
$88,094.54/yr
Blended yield
23.52%
📊

Analyst Conviction Gap

Where Wall Street is most bullish on JNJ right now

KMSTF
No analyst data
Altman Z
-328.3
Piotroski
2/9
JNJ
Analyst Ratings
20
Buy
17
Hold
3
Sell
Consensus: Buy
Price Target
$228.73
+55.1% upside vs current
Range: $190.00 — $265.00
Altman Z
5.2
Piotroski
4/9
Analyst ratings via FMP. Altman Z-Score: >3.0 safe, 1.81–3.0 grey zone, <1.81 distress. Piotroski: 7–9 strong, 0–3 weak.
🏛️

Copy Congress — What Are Politicians Buying?

Senate & House STOCK Act disclosures (last 90 days)

KMSTF buys
0
JNJ buys
0
No recent congressional trades found for KMSTF or JNJ in the last 90 days.
STOCK Act mandates disclosure within 45 days of transaction. Data via FMP.Full tracker →
MetricKMSTFJNJ
Forward yield62.31%3.36%
Annual dividend / share$2.00$4.96
Payout ratio50%55%
1-year div growth0%4.2%
5-year div CAGR0%5.8%
Portfolio after 10y$729.0K$20.0K
Annual income after 10y$175,361.30$827.78
Total dividends collected$608.8K$5.6K
Payment frequencyquarterlyquarterly
SectorStockHealthcare

Year-by-year: KMSTF vs JNJ ($10,000, DRIP)

YearKMSTF PortfolioKMSTF Income/yrJNJ PortfolioJNJ Income/yrGap
1← crossover$16,931$6,230.53$10,676$355.77+$6.3KKMSTF
2$27,974$9,858.52$11,407$389.39+$16.6KKMSTF
3$45,156$15,223.51$12,198$426.53+$33.0KKMSTF
4$71,283$22,966.14$13,056$467.62+$58.2KKMSTF
5$110,155$33,882.50$13,987$513.12+$96.2KKMSTF
6$166,800$48,934.07$14,998$563.56+$151.8KKMSTF
7$247,726$69,249.85$16,098$619.52+$231.6KKMSTF
8$361,186$96,119.21$17,295$681.69+$343.9KKMSTF
9$517,443$130,974.20$18,599$750.82+$498.8KKMSTF
10$729,026$175,361.30$20,022$827.78+$709.0KKMSTF

KMSTF vs JNJ: Complete Analysis 2026

KMSTFStock

Kadimastem Ltd, a biopharmaceutical company, develops regenerative medicine therapies based on cells derived from human embryonic stem cells to treat neuro-degenerative diseases. Its products in pipeline include AstroRx, a clinical grade human astrocytes that is in Phase 1/2a clinical trial for the treatment of amyotrophic lateral sclerosis and other neurodegenerative diseases; and IsletRx, a clinical grade pancreatic islet cell therapy treatment for diabetes. The company was founded in 2008 and is based in Ness Ziona, Israel.

Full KMSTF Calculator →

JNJHealthcare

Johnson & Johnson is a Dividend King with 62+ years of consecutive dividend increases. A healthcare conglomerate spanning pharmaceuticals, MedTech, and consumer health. JNJ spun off its consumer segment as Kenvue in 2023, focusing on higher-margin pharma and medical devices.

Full JNJ Calculator →
📬

Get this KMSTF vs JNJ comparison by email

Save your analysis + weekly dividend insights. Free forever.

More comparisons

KMSTF vs SCHDKMSTF vs JEPIKMSTF vs OKMSTF vs KOKMSTF vs MAINKMSTF vs ABBVKMSTF vs MRKKMSTF vs PFE

⚠️ Educational purposes only. Not financial advice. Congressional trades sourced from SEC STOCK Act filings via FMP. Past performance does not guarantee future results.